Anti-Human IL-6 (Sarilumab) Dylight® 488 Biosimilar (IVMB0463)
- SKU:
- IVMB0463
- Antibody Type:
- Dylight Biosimilar
- Applications:
- Drug Development
- Inflammation Assays
- Inflammatory Response Assays
- Pharmacokinetics
- Disease Area:
- Inflammatory Diseases
- Disease Area:
- Autoimmune Disorders
Description
| Product Name: | Anti-Human IL-6 (Sarilumab) Dylight 488 |
| SKU: | IVMB0463 |
| Size: | 100 µg |
| Antibody Type: | Biosimilar Recombinant Human Monoclonal Antibody |
| Clone: | Hu137 |
| Target: | IL-6 |
| Isotype: | Human IgG1κ |
| Host Species: | Human |
| Reactivity: | Human |
| Applications: | FA |
| Expression Host: | HEK-293 Cells |
| FC Effector Activity: | Active |
| Synonyms: | Interleukin-6, CDF; HGF; HSF; BSF2; BSF-2; IFNB2; IFN-beta-2 |
| Product Concentration: | 0.2 mg/ml |
| Excitation Laser: | Blue Laser (493 nm) |
| Applications and Recommended Usage: | FC The suggested concentration for Alemtuzumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. |
| Antigen Distribution: | IL-6R is ubiquitously expressed. |
| Formulation: | This DyLight 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. |
| Specificity: | This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Sarilumab. Sarilumab binds to the transmembrane and soluble forms of the IL-6 receptor. This product is for research use only. |
| Additional Applications Reported In Literature: | IHC (Paraffin)IHC (Frozen) |
| Additional Reported Applications For Relevant Conjugates: | FAWBBN |
IL-6 and its signaling pathway play a part in immune response regulation, inflammation, and hematopoiesis.2 Sarilumab is a research-grade recombinant human monoclonal IL-6 receptor antagonist. It specifically binds to both the transmembrane and soluble forms of the IL-6 receptor, thus inhibiting IL-6–mediated cis and trans-signaling in a dose-dependent manner.1 Therapeutic Sarilumab, also known by the trade name Kevzara, is currently used to treat Rheumatoid Arthritis1, however, as of March 2020, The Feinstein Institute of Northwell Health publicized a study on "a human antibody that may prevent the activity" of IL-6 for the treatment of COVID-19.3 Anti-Human IL-6 (Sarilumab) utilizes the same variable regions from the therapeutic antibody Sarilumab making it ideal for research projects.
| Regulatory Status: | Research Use Only (RUO). Non-Therapeutic. |
| Storage and Handling: | This DyLight 488 conjugate is stable when stored at 2-8°C.Do not freeze. |
| Research Area: | Biosimilars |
Related Products
Anti-Human IL 12/23 (Briakinumab) Dylight® 488 Biosimilar (IVMB0511)
Anti-Human IL-2R alpha (CD25) (Basiliximab) - Dylight® 488 Biosimilar (IVMB0498)
Anti-Human IL-6 (Sarilumab) - HRP Biosimilar (IVMB0458)
Anti-Human IL-6 (Sarilumab) - APC Biosimilar (IVMB0459)
